「validation」の検索結果

Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2/PE3/PE3b/PEmax variants, MOSAIC in situ saturation mutagenesis, the PRIME pooled-screen methodology (Ren 2023; ~3,699 ClinVar variant screens), chromatin context as a major locus-level determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.

日本語の概要は準備中です。原文の説明を表示しています。

Discover RBP binding motifs from CLIP-seq peaks or single-nucleotide crosslink sites using HOMER, MEME/STREME, kpLogo, mCross (CL-position-registered motifs), PEKA (positional k-mer enrichment), RBPamp (affinity), and RNA Bind-n-Seq (RBNS) cross-validation. Use when characterizing RBP sequence specificity, registering motifs to crosslink positions, validating in vivo CLIP motifs against in vitro RBNS Kd, reconciling motif disagreements across tools, or correcting for the uracil crosslinking bias that contaminates raw CLIP motif logos.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes base-editing screens for variant function. Covers library design (Hanna 2021 ClinVar-scale CBE screen benchmarked on BRCA1/2, Cuella-Martin 2021 DDR saturation), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end; 4-7 for ABE7.10), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.

日本語の概要は準備中です。原文の説明を表示しています。

Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.

日本語の概要は準備中です。原文の説明を表示しています。

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

日本語の概要は準備中です。原文の説明を表示しています。

Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.

日本語の概要は準備中です。原文の説明を表示しています。

Guidance for SPR and BLI binding characterization experiments. Use when: (1) Planning binding kinetics experiments, (2) Troubleshooting poor/no binding signal, (3) Interpreting kinetic data artifacts, (4) Choosing between SPR vs BLI platforms.

日本語の概要は準備中です。原文の説明を表示しています。

Validate alignment quality with insert size distribution, proper pairing rates, GC bias, strand balance, and other post-alignment metrics. Use when verifying alignment data quality before variant calling or quantification.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end binder design using BindCraft hallucination. Use this skill when: (1) Designing protein binders with built-in AF2 validation, (2) Running production-quality binder campaigns, (3) Using different design protocols (fast, default, slow), (4) Need joint backbone and sequence optimization, (5) Want high experimental success rate. For backbone-only generation, use rfdiffusion. For QC thresholds, use protein-qc. For tool selection guidance, use binder-design.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive backend development guide for Langfuse's Next.js 14/tRPC/Express/TypeScript monorepo. Use when creating tRPC routers, public API endpoints, BullMQ queue processors, services, or working with tRPC procedures, Next.js API routes, Prisma database access, ClickHouse analytics queries, Redis queues, OpenTelemetry instrumentation, Zod v4 validation, env.mjs configuration, tenant isolation patterns, or async patterns. Covers layered architecture (tRPC procedures → services, queue processors → services), dual database system (PostgreSQL + ClickHouse), projectId filtering for multi-tenant isolation, traceException error handling, observability patterns, and testing strategies (Jest for web, vitest for worker).

日本語の概要は準備中です。原文の説明を表示しています。

API security testing workflow for REST and GraphQL APIs covering authentication, authorization, rate limiting, input validation, and security best practices.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze market conditions, geographic opportunities, pricing, consumer behavior, and product validation across Google Maps, Facebook, Instagram, Booking.com, and TripAdvisor.

日本語の概要は準備中です。原文の説明を表示しています。

Builds production-ready REST API endpoints with validation, error handling, authentication, and documentation. Follows best practices for security and scalability.

日本語の概要は準備中です。原文の説明を表示しています。

Implement secure API design patterns including authentication, authorization, input validation, rate limiting, and protection against common API vulnerabilities

日本語の概要は準備中です。原文の説明を表示しています。

When the user needs to generate, iterate, or scale ad creative for paid advertising. Use when they say 'write ad copy,' 'generate headlines,' 'create ad variations,' 'bulk creative,' 'iterate on ads,' 'ad copy validation,' 'RSA headlines,' 'Meta ad copy,' 'LinkedIn ad,' or 'creative testing.' This is pure creative production — distinct from paid-ads (campaign strategy). Use ad-creative when you need the copy, not the campaign plan.

日本語の概要は準備中です。原文の説明を表示しています。

Multi-layer validation to catch bugs before they escape

日本語の概要は準備中です。原文の説明を表示しています。

Harvests a DESIGN.md from an existing codebase, critiques it against the actual code, and applies safe quick-win fixes. Three modes harvest / critique / fix. Shells out to `npx @google/design.md lint` for structural validation; never reimplements Google's linter. The on-ramp that makes DESIGN.md adoptable for every existing repo, not just greenfield projects.

日本語の概要は準備中です。原文の説明を表示しています。

Plan and implement infrastructure, CI/CD, container, deployment, observability, and operational configuration changes with least privilege, staged validation, and rollback awareness. Use for pipelines, infrastructure as code, Kubernetes, containers, release automation, monitoring, and production-readiness work; do not use to perform destructive production actions without explicit authorization.

日本語の概要は準備中です。原文の説明を表示しています。

Deep-dive framework for analyzing crypto tokens — market data, liquidity health, tokenomics, unlock schedules, and risk assessment. Combines on-chain data, API queries, and multi-source validation to generate actionable investment verdicts.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level medical device design covering regulatory pathways, design controls, biocompatibility, sterilization, risk management, and verification and validation.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level analytical chemistry knowledge. Use when working with chromatography, spectroscopy, electroanalytical methods, sample preparation, quantitative analysis, calibration, statistics, or instrumental analysis. Also use when the user mentions 'HPLC', 'GC', 'mass spectrometry', 'atomic absorption', 'ICP', 'titration', 'calibration curve', 'detection limit', 'NMR', 'chromatography', 'electrochemistry', 'sample preparation', or 'method validation'.

日本語の概要は準備中です。原文の説明を表示しています。

Planifie le prochain sprint : calcule la capacité (vélocité glissante 3 sprints), reporte les tickets non livrés du sprint courant, puis complète depuis le backlog par priorité jusqu'à la capacité. Présente le plan, attend validation, puis assigne les tickets au sprint. Usage: /plan-sprint [<titre-sprint-cible>]

日本語の概要は準備中です。原文の説明を表示しています。

Validate a PRD against standards. Use when the user says "validate this PRD" or "run PRD validation"

日本語の概要は準備中です。原文の説明を表示しています。

Route data analysis and machine learning work to the right skill in this suite. Use when starting any analysis, modeling, validation, or reproducibility task and the matching specialized skill is not yet clear; not needed when one specific skill already clearly applies.

日本語の概要は準備中です。原文の説明を表示しています。